Announcing the "Portable Expiratory CO Concentration Measuring Device Integrated Therapeutic Application" IoT Device.

We have developed the "Portable Expiratory CO Concentration Measuring Device Integrated Therapeutic Application" IoT Device to allow for the measurement of exhaled carbon monoxide (CO) concentrations in smoking cessation treatments in the field of telemedicine.

In recent years, the government's Future Investment Conference and the Ministry of Health, Labor and Welfare have been discussing about the expansion of insurance applications to telemedicine. Smoking cessation therapy has become a hot topic. One of the challenges have been that one of the main conditions for the current insurance application, the measurement of the carbon monoxide (CO) concentration in breath, cannot be performed remotely. Patients must attend a medical facility to obtain these results.
We are proud to announce that CureApp Inc. (Headquarters: Chuo-ku, Tokyo, President and CEO: Kota Satake) offers a "portable IoT device" that enables patients to measure breath CO concentrations for remote diagnosis. This allows confirmation of the measurement result to be completed by patients and doctors · We are pleased to announce that we have developed a unique solution by integrating the "Nicotine Addiction Treatment Application · Cloud". (Patent pending).

Measurement of CO concentration levels in breath is an objective indicator of the success or failure of smoking cessation treatment. Such measurements are important and stipulations state that they should be made regularly. However, conventional exhaled CO concentration measuring instruments are not available for personal use due to their size and inconvenience of having it at home, therefore patients have to visit medical institutions for such measurements. With this this type of clinical need in mind, we have made it possible to measure the exhaled breath CO concentration daily at home and out-of-hospital even in telemedicine. To improve the accuracy of the course of treatment we have developed an IoT device with the following three features: (1) a miniaturized device for portability, (2) cost reduction and (3) visibly high frequency measurement results.

As stated by our President, CEO and pulmonologist Mr. Kota Satake: In smoking cessation therapy One is sometimes asked why it is necessary to pay medical expenses for personal luxury goods, but from the viewpoint of insurance providers who are responsible for the burden of cost and public satisfaction, such monitoring is required.. "

[An Outline of the Integrated Therapeutic Application for the Portable Expiratory CO Concentration Measuring Device]

I.Miniaturization and Weight Reduction
Because the device was made smaller and lighter, it can be carried at home, when not at the hospital, for use in telemedicine treatment allowing daily exhaled CO concentration measurements to be possible.

(A) A Conventional product is 180 – 200 g while our product is half that weight at 100g.
(B) A compact design with the following measurements: Length: 13.7 cm, width: 4.2 cm, height: 3.6 cm.

II. Low Cost
By thoroughly reviewing the manufacturing processes and carefully selecting parts and suppliers, we were able to achieve a cost reduction not present in previous products.

III. Visualizing Measurement Results More Frequently
As individual patients have portable expiratory CO concentration measuring instruments, it is possible at to have measurements at the time of consultation (in a non-smoking outpatient, to have daily measurements, not just monthly measurements), as well as the results of daily measurements to allow patients to see a better picture of their results.

IV. Improvement of "Treatment Vacancy"
Utilizing a treatment application fills the gaps of "treatment vacancies" that occur between examinations with objective data. By inputting the exhaled CO concentration measurement result on a daily basis, through the application, we will be better able to understand the current condition of the patient and provide appropriate guidance to each individual.

[CureApp Company Outline]
Company name: CureApp Inc.
Representative Director and President: Kota Satake
Location: Nihonbashi Koibu-cho, Chuo-ku, Tokyo No. 1 CASTELLINO O.T. NIHONBASHI 7th Floor
Capital and Capital Reserve: 484,100,000 JPY
Establishment: July 31, 2014
Business Description: Medical Equipment Development, PHR (Personal Health Record) Business, Mobile Health Related Service Business
URL: http://cureapp.co.jp/

[Inquiries Concerning this Matter]
CureApp Inc. Public Relations Mishima
support@cureapp.jp

[About our Business]
CureApp, Inc. is a MedTech venture from R & D to manufacturing and sales of medical treatment equipment based on advanced software technology and medical evidence.

In order to realize a new medical service in Japan where "an application has the effect of treating diseases" for the first time, we are working on the development of a "treatment application" which is an application to treat diseases.

A "Treatment application" aims to generate new effective treatments by analysis and guidance via an application based on medical knowledge and evidence based on the daily treatment course of each patient.

It also has the possibility of contributing to the fundamental improvement of disease treatment by encouraging the improvement of patient behavioral habits from the alteration of awareness and behavior. In Japan, we have begun conducting clinical trials and have started applying application usage for monitoring multiple diseases.

The development status of the current "treatment application" is as follows:

· Application for treatment of nicotine addiction: joint development with respiratory internal medicine department of Keio University School of Medicine, multicenter cooperative clinical trial has been in progress since February 2015.

· Nonalcoholic steatohepatitis (NASH) treatment application: Collaborative research with the University Hospital affiliated hospital. Clinical research has been in progress since October 2016.

※ "Treatment application" is a registered trademark of CureApp, Inc.

In addition, we have started to develop a "health management support program" for corporations so that the knowledge accumulated in the development of "therapeutic applications" for medical institutions can be utilized for promoting the health of private enterprises.

ascure smoking cessation program will be offered in April 2017

URL: https://www.ascure.technology/


[References]
1 Nicotine addiction management fee information facility standard (4)